Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Eleven Biotherapeutics Inc (EBIO) Soars On Lead Drug News; Hedge Funds Are Bullish

Eleven Biotherapeutics Inc (NASDAQ:EBIO)’s stock surged by more than 230% in the first hours of trading today, which offset the stock’s slump from the last couple of months. Eleven Biotherapeutics has revealed that it started administering EBI-005 to its first patients in a late-stage study aimed to discover the drug’s efficacy in treating moderate to severe allergic conjunctivitis. The stock later retracted and currently trades at around 90% in green. However, Eleven Biotherapeutics is a micro-cap stock, which is prone to large price fluctuations. Nevertheless, let’s take a closer look at the news and see the hedge fund sentiment surrounding the stock to understand its potential as an investment opportunity.

The patient dosing represents an important part of Eleven Biotherapeutics’ Phase 3 study of EBI-005 and the company expects to present top-line data in the first three months of the next year. EBI-005 is the most advanced product candidate of Eleven Biotherapeutics and represents a topically-administered receptor blocker in development as a protein therapeutic for inflammatory diseases of the eye. In May, the company reported weak results from the Phase 3 pivotal study, which did not meet the primary endpoints and showed no statistical difference between EBI-005 and vehicle control. On the back of pivotal study results, the stock slumped by 75% and despite today’s jump, the stock is still down by 51% year-to-date.


Due to its small size, Eleven Biotherapeutics does not enjoy a lot of popularity from smart money, as only eight funds from our database held long positions at the end of March. We consider hedge fund sentiment an important metric, because this group of investors spends a lot of resources to identify profitable opportunities in the markets. Through extensive research, we determined that hedge funds’ best ideas are represented by their small-cap picks. Based on our studies, we determined that a portfolio of 15 most popular small-cap stocks among hedge funds can beat the market by double digits annually and since we started tracking these stocks in real time, in August 2012, this approach has provided gains of over 123%, having outperformed the S&P 500 ETF (SPY) by around 65 percentage points (read more details here). Considering these, we’re going to take a glance at the new hedge fund activity regarding Eleven Biotherapeutics Inc.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.